Validation of a Virtual Reality Test for the Assessment of Visually Impaired Patients Undergoing Low Vision Rehabilitation

NCT07092124 · tracked via the Priya Life Science France tracker

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Phase

Not applicable

Started

2025-10-30

Last updated

2025-11-28

Condition(s) studied

Low Vision

Investigational drug(s) / intervention(s)

test visionumVR

test visionumVR: Two evaluation sessions with VisionumVR one month apart

Study summary

Low vision rehabilitation is a vital part of care for visually impaired patients, who are usually referred to orthoptists to develop visual strategies and optimize residual vision. This rehabilitation significantly improves quality of life by enhancing autonomy and reducing depression. It employs various tools, from traditional exercises to specialized software. Advances in virtual reality (VR) offer new promising opportunities by creating immersive environments tailored to patients' residual vision, increasing motivation and exercise effectiveness. In this context, VisionumVR was developed-a VR test using the Meta Quest 3 headset to assess functional vision during rehabilitation. It evaluates hand-eye coordination, visual discrimination, and visual exploration through a daily-life-inspired task. This standardized 20-minute test aims to measure patients' progress throughout their orthoptic rehabilitation.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patient (regardless of visual pathology) who is about to begin or has begun orthoptic low vision rehabilitation; * Patient requiring at least five orthoptic rehabilitation sessions that can be completed before the end of the study; * Binocular visual acuity ≥ 1/20 (≤ 1.3 logMAR), regardless of type of vision loss (central, mixed, or peripheral); * Sufficient knowledge of the French language. Exclusion Criteria: * Neurodegenerative diseases or any other condition that could interfere with the planned assessments in this study (known epilepsy and/or history of seizures, dysfunction of the dominant upper limb, etc.); * Medications that may cause motor, visual, or cognitive impairments (neuroleptics, etc.) or interfere with the study assessments; * Pregnant women (pregnancy can cause vision fluctuations, and wearing a virtual reality headset is not recommended); * Participation in another clinical trial that may interfere with the current study; * Inability to follow instructions or read.

Primary outcome measure(s)

repetability — Day 0 and Month 1
Repeatability coefficient of performance on the VisionumVR test

Trial sites (2)

Facility	City	Region	Status
Centre Régional Basse Vision et Trouble de l'Audition	Angers	France	Recruiting
Institut de Réadaptation Visuelle Saint-Louis	Paris	France	Recruiting

More Fondation Ophtalmologique Adolphe de Rothschild trials in France

Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months Recruiting

Anatomical and Functional Predictions of Blindsight Capabilities in Patients With Lateral Hemianopsia Starting soon

Long Term Follow-up After Embolization of Brain Arteriovenous Malformations Recruiting

Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations Recruiting

Optimization of Sequences to Improve the Quality and Comfort of the Magnetic Resonance Imaging Examination Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07092124 on ClinicalTrials.gov ↗ ← All trials in France